The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2019 | GEM-CESAR at EHA 2019: curative treatment strategy for high-risk smoldering myeloma
Maria-Victoria Mateos, MD, PhD, from the Institute of Biomedical Research of Salamanca, Salamanca, Spain, discusses the latest news from the GEM-CESAR trial (NCT02415413) of a curative treatment strategy for high-risk smoldering myeloma: KRD as induction, followed by HDT-ASCT, KRD consolidation and maintenance with RD. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.
